Lineage Cell Therapeutics
(NYSEMKT) LCTX
Lineage Cell Therapeutics Financials at a Glance
Market Cap
$319.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$14.78M
Net Income (TTM)
-$64.21M
EPS (TTM)
-$0.29
P/E Ratio
-4.45
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$1.28
Volume
738,914
Open
$1.29
Price
$1.28
Volume
738,914
Open
$1.29
Previous Close
$1.28
Daily Range
$1.25 - $1.30
52-Week Range
$0.93 - $2.09
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.12 (Average)
Price
$1.28
Volume
738,914
Open
$1.29
Previous Close
$1.28
Daily Range
$1.25 - $1.30
52-Week Range
$0.93 - $2.09
Estimated Earnings Date
Aug 11, 2026
LCTX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Lineage Cell Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
77
CEO
Brian M. Culley, MBA
Website
www.lineagecell.comHeadquarters
Carlsbad, CA 92008, US
LCTX Financials
Key Financial Metrics (TTM)
Gross Margin
97.98%
Operating Margin
-255.14%
Net Income Margin
-434.44%
Return on Equity
-152.10%
Return on Capital
-46.37%
Return on Assets
-58.62%
Earnings Yield
-22.47%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$319.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
249.30M
Volume
738.91K
Avg. Volume
1.53M
Financials (TTM)
Gross Profit
$14.48M
Operating Income
-$37.71M
EBITDA
-$43.15M
Operating Cash Flow
-$22.11M
Capital Expenditure
-$192.00K
Free Cash Flow
-$22.30M
Cash & ST Invst.
$53.38M
Total Debt
$2.39M
Lineage Cell Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.73M
+14.8%
Gross Profit
$1.54M
+4.8%
Gross Margin
89.10%
N/A
Market Cap
$319.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$4.25M
N/A
Employees
75
N/A
Net Income
-$4.81M
-16.3%
EBITDA
-$4.60M
-15.6%
Quarterly Fundamentals
Total Cash
$53.38M
+11.4%
Total Debt
$2.39M
+6.7%
Accounts Receivable
$806.00K
+278.4%
Inventory
$0.00
N/A
Long Term Debt
$1.53M
+43.7%
Short Term Debt
$865.00K
-26.7%
Return on Assets
-58.62%
N/A
Return on Invested Capital
-37.19%
N/A
Free Cash Flow
-$8.13M
-63.2%
Operating Cash Flow
-$8.08M
-65.3%